A Phase 2 interventional study of SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-04-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 8th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 14th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2008.
This study's enrollment of 185 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 3 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aims of the trial are to assess the safety and the efficacy of SPM 962 following once-a-daily transdermal administration within a range of 2.25 to 6.75 mg/day in Japanese patients with restless legs syndrome (RLS) in a multi-center, open-label trial. The maximum treatment period is 53 weeks. The trial is an extension trial from the precedent 6-week, double-blind, randomized, placebo-controlled, parallel-group comparative trial(243-07-003). The trial is also for an exploratory investigation of incidence of augmentation, the most problematic complications in dopaminergic treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine transdermal patch
Drug: SPM 962
Tansdermal patch
Also known as: rotigotine
The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters
The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of adverse events, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion
Time frame: Up to 54 weeks
Augmentation
Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Augmentation is clinically significant when at least one of the following occurs: 1. Change in daily activities and/or behavior (e.g., the patient stops riding in cars in the afternoon) due to augmentation; 2. Negative impact on the patient's quality of life (sleep, mood, etc.) due to augmentation; 3. Need to change the treatment dose or the patient needs to take the dose earlier in the day (e.g., dividing the dose); 4. Adjustments in concomitant medication are made to compensate for augmented RLS symptoms (e.g., an increased intake of analgesics or hypnotics to cover an increase in symptom intensity); 5. Any other aspect as judged by the evaluator (should be specified).
Time frame: Up to 53 weeks
Change of the Pittsburgh Sleep Quality Index (PSQI) From Baseline to Each Visit
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.
Time frame: Baseline, Up to 53 weeks
Change of IRLS Sum Score From the Baseline to Each Visit
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
Time frame: Baseline, Up to 53 weeks
Efficacy Rate in IRLS Sum Score
Efficacy rate (percentage of subjects with 50% decrease) (LOCF) in IRLS sum score.
Time frame: Baseline, Up to 53 weeks
Change of Augmentation Severity Rating Scale (ASRS) Sum Score From Baseline to Each Visit
ASRS is a scale for assessing severity of augmentation. ASRS consists of 3 items (one item containing 4 sub-items). The sum of the score of each question serves as the scale score (each question score: 0-3, sum score 0-24). A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Time frame: Baseline, Up to 52 weeks
Change of Short-Form 36-Item Health Survey (SF-36) From Baseline to Each Visit
SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.
Time frame: Baseline, Up to 53 weeks
| Milestone | SPM 962 |
|---|---|
| Started | 185 |
| Completed | 133 |
| Not completed | 52 |
| Withdrew: Adverse event | 29 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Withdrawal by subject | 13 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Discontinuation criteria | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Physician decision | 2 |
The safety of the long-term SPM 962 treatment was examined based on the incidence and severity of adverse events, vital signs, and laboratory parameters. AEs of special interest (1-3) are defined as below: 1. sudden onset of sleep 2. obsessive-compulsive disorder or impulse-control disorder 3. hallucination, delusion
| participants | SPM 962 |
|---|---|
| Any AEs | 175 |
| Treatment-related AEs | 139 |
| SAEs | 5 |
| Treatment-related SAEs | 1 |
| Severe AEs | 3 |
| Discontinuation due to AEs | 29 |
| Death | 0 |
| AEs of special interest 1 | 0 |
| AEs of special interest 2 | 0 |
| AEs of special interest 3 | 0 |
| Valvular disease of the heart | 0 |
Augmentation is the main complication during long-term dopaminergic treatment of restless legs syndrome (RLS) and reflects an overall increase in RLS severity. Augmentation is clinically significant when at least one of the following occurs: 1. Change in daily activities and/or behavior (e.g., the patient stops riding in cars in the afternoon) due to augmentation; 2. Negative impact on the patient's quality of life (sleep, mood, etc.) due to augmentation; 3. Need to change the treatment dose or the patient needs to take the dose earlier in the day (e.g., dividing the dose); 4. Adjustments in concomitant medication are made to compensate for augmented RLS symptoms (e.g., an increased intake of analgesics or hypnotics to cover an increase in symptom intensity); 5. Any other aspect as judged by the evaluator (should be specified).
| participants | SPM 962 |
|---|---|
| Subjects with augmentation | 11 |
| Subjects with clinically significant augmentation | 5 |
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Weeks 8 | -11.4 ± 8.8 |
| Week 16 | -9.7 ± 9.6 |
| Week 32 | -9.5 ± 9.1 |
| Week 44 | -10.4 ± 9.1 |
Efficacy rate (percentage of subjects with 50% decrease) (LOCF) in IRLS sum score.
| Percentage of participants | SPM 962 |
|---|---|
| Weeks 8 | 64.1 (57.2 to 71.1) |
| Week 16 | 54.9 (47.7 to 62.1) |
| Week 32 | 57.6 (50.5 to 64.7) |
| Week 44 | 60.3 (53.3 to 67.4) |
ASRS is a scale for assessing severity of augmentation. ASRS consists of 3 items (one item containing 4 sub-items). The sum of the score of each question serves as the scale score (each question score: 0-3, sum score 0-24). A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 8 | 1.4 ± 2.5 |
| Week 16 | 1.4 ± 2.6 |
| Week 32 | 1.6 ± 2.7 |
| Week 44 | 1.4 ± 2.6 |
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Week 8 | -2.2 ± 3.3 |
| Week 16 | -2.2 ± 2.9 |
| Week 44 | -2.0 ± 3.1 |
SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.
| Scores on a scale | SPM 962 |
|---|---|
| Physical functioning | -0.2 ± 8.0 |
| Role physical | 3.7 ± 17.4 |
| Bodily pain | 5.1 ± 22.3 |
| General health | 1.8 ± 12.8 |
| Vitality | 4.9 ± 15.8 |
| Social functioning | 3.0 ± 16.2 |
| Role emotional | 5.6 ± 14.5 |
Collected over 53 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPM 962 | — | 5/185 (2.7%) | 165/185 (89.2%) |
| Event | SPM 962 |
|---|---|
| CataractEye disorders | 1/185 |
| Diverticulitis Intestinal HaemorrhagicGastrointestinal disorders | 1/185 |
| Application Site DiscolourationGeneral disorders | 1/185 |
| ContusionInjury, poisoning and procedural complications | 1/185 |
| Neck CrushingInjury, poisoning and procedural complications | 1/185 |
| Nerve Root Injury LumbarInjury, poisoning and procedural complications | 1/185 |
| Traffic AccidentInjury, poisoning and procedural complications | 1/185 |
| HaematomaVascular disorders | 1/185 |
| Event | SPM 962 |
|---|---|
| NasopharyngitisInfections and infestations | 97/185 |
| Application Site ReactionGeneral disorders | 85/185 |
| NauseaGastrointestinal disorders | 53/185 |
| SomnolencePsychiatric disorders | 29/185 |
| HeadacheNervous system disorders | 25/185 |
| VomitingGastrointestinal disorders | 15/185 |
| DiarrhoeaGastrointestinal disorders | 12/185 |
| Application Site PruritusGeneral disorders | 12/185 |
| FallInjury, poisoning and procedural complications | 11/185 |
| Abdominal Pain UpperGastrointestinal disorders | 10/185 |
| Age, Categorical(Participants) | SPM 962 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 157 |
| >=65 years | 28 |
| Age, Continuous(years) | SPM 962 |
|---|---|
| Mean | 49.8 ± 13.1 |
| Sex: Female, Male(Participants) | SPM 962 |
|---|---|
| Female | 113 |
| Male | 72 |
| Region of Enrollment(participants) | SPM 962 |
|---|---|
| Japan | 185 |
No study locations are listed for this record.
The record gives a start of Aug 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →